IN2014CN04014A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04014A
IN2014CN04014A IN4014CHN2014A IN2014CN04014A IN 2014CN04014 A IN2014CN04014 A IN 2014CN04014A IN 4014CHN2014 A IN4014CHN2014 A IN 4014CHN2014A IN 2014CN04014 A IN2014CN04014 A IN 2014CN04014A
Authority
IN
India
Prior art keywords
compounds
prophylaxis
modulators
channels
formula
Prior art date
Application number
Inventor
Giuseppe Alvaro
Agostino Marasco
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2011/052414 external-priority patent/WO2012076877A1/en
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of IN2014CN04014A publication Critical patent/IN2014CN04014A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The invention provides compounds of formula (I): Said compounds being modulators of Kv3 channels and of use in the prophylaxis or treatment of related disorders.
IN4014CHN2014 2011-12-06 2012-12-06 IN2014CN04014A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2011/052414 WO2012076877A1 (en) 2010-12-06 2011-12-06 Hydantoin derivatives useful as kv3 inhibitors
PCT/GB2012/053045 WO2013083994A1 (en) 2011-12-06 2012-12-06 Hydantoin derivatives useful as kv3 inhibitors

Publications (1)

Publication Number Publication Date
IN2014CN04014A true IN2014CN04014A (en) 2015-07-10

Family

ID=47429936

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4014CHN2014 IN2014CN04014A (en) 2011-12-06 2012-12-06

Country Status (14)

Country Link
EP (1) EP2788339B1 (en)
JP (1) JP5985651B2 (en)
KR (1) KR20140098850A (en)
CN (1) CN103974944B (en)
AU (1) AU2012349847B2 (en)
CA (1) CA2856654C (en)
DK (1) DK2788339T3 (en)
ES (1) ES2576628T3 (en)
HK (1) HK1203072A1 (en)
IL (2) IL232612B (en)
IN (1) IN2014CN04014A (en)
MX (1) MX356813B (en)
PL (1) PL2788339T3 (en)
WO (1) WO2013083994A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103596943B (en) 2011-06-07 2016-10-12 奥蒂福尼疗法有限公司 Hydantoin derivatives as KV3 inhibitor
EP2852588B8 (en) 2012-05-22 2018-01-10 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
WO2013182851A1 (en) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
WO2018220762A1 (en) * 2017-05-31 2018-12-06 大塚製薬株式会社 Pyrimidine compound
JP2022502370A (en) 2018-09-21 2022-01-11 バイオノミクス リミテッド Substituted pyridinyl compounds and their use
JP7465868B2 (en) * 2018-10-16 2024-04-11 アウトイフオンイ トヘラペウトイクス リミテッド New Compounds
CA3169057A1 (en) * 2020-02-06 2021-08-12 Autifony Therapeutics Limited Kv3 modulators
CA3226856A1 (en) 2021-08-10 2023-02-16 Autifony Therapeutics Limited Potassium channel modulators
CN117448440A (en) * 2023-10-23 2024-01-26 中国人民解放军空军军医大学 Application of Kv3 in preparation of product for diagnosing or treating abnormal fear memory fading of post-traumatic stress disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675403A (en) * 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
DK123493D0 (en) * 1993-11-01 1993-11-01 Lundbeck & Co As H COMPOUNDS
CN102256968A (en) * 2008-12-22 2011-11-23 弗·哈夫曼-拉罗切有限公司 Heterocyclic antiviral compounds
BR112012015868A2 (en) * 2009-12-11 2017-06-20 Autifony Therapeutics Ltd imidazolidinedione derivatives
CN102652134A (en) * 2009-12-14 2012-08-29 弗·哈夫曼-拉罗切有限公司 Heterocyclic antiviral compounds
SG190203A1 (en) * 2010-12-06 2013-06-28 Autifony Therapeutics Ltd Hydantoin derivatives useful as kv3 inhibitors
CN103596943B (en) * 2011-06-07 2016-10-12 奥蒂福尼疗法有限公司 Hydantoin derivatives as KV3 inhibitor

Also Published As

Publication number Publication date
IL258704A (en) 2018-06-28
IL232612A0 (en) 2014-06-30
DK2788339T3 (en) 2016-05-23
EP2788339B1 (en) 2016-03-09
CA2856654C (en) 2020-03-31
AU2012349847A1 (en) 2014-06-26
ES2576628T3 (en) 2016-07-08
PL2788339T3 (en) 2016-09-30
WO2013083994A1 (en) 2013-06-13
JP2015502951A (en) 2015-01-29
KR20140098850A (en) 2014-08-08
MX2014006753A (en) 2014-10-15
EP2788339A1 (en) 2014-10-15
CA2856654A1 (en) 2013-06-13
CN103974944A (en) 2014-08-06
JP5985651B2 (en) 2016-09-06
IL258704B (en) 2019-05-30
CN103974944B (en) 2016-11-02
AU2012349847B2 (en) 2017-02-16
MX356813B (en) 2018-06-13
IL232612B (en) 2018-07-31
HK1203072A1 (en) 2015-10-16

Similar Documents

Publication Publication Date Title
IN2014CN04014A (en)
MX338489B (en) Hydantoin derivatives useful as kv3 inhibitors.
PH12015500525A1 (en) Formulations of enzalutamide
PH12015502788A1 (en) Antibody formulations and methods
TR201813877T4 (en) COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY.
IN2015DN01156A (en)
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
PH12015502161A1 (en) Therapeutic compounds and compositions
MX356525B (en) Aav -vectors for use in gene therapy of choroideremia.
MX2013015311A (en) Pcsk9-binding polypeptides and methods of use.
MX2014011134A (en) Carbamate compounds and of making and using same.
MX2013008390A (en) Preparation of metal-triazolate frameworks.
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
MX354988B (en) Antibody formulations and methods.
MX360710B (en) Antagonists of il17c for the treatment of inflammatory disorders.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
EA201491894A1 (en) METHODS OF TREATMENT OF Lactose Intolerance
MX2014015039A (en) Fbxo3 inhibitors.
MX2013002121A (en) Substituted quinoline-3-carboxamides as kcnq2/3 modulators.
MX359181B (en) Collagen hydrolysate and use thereof.
IN2014DN00254A (en)
MX2016003293A (en) Methods and compositions for treatment of chlamydial infection and related diseases and disorders.
UA117567C2 (en) Galactagogue compositions based on phosphatidylserine
EA201491522A1 (en) METHODS OF TREATING DISORDERS OF GAIT AND / OR BALANCE IN PATIENTS WITH MULTIPLE SCLEROSIS USING AMINOPYRIDINE
PH12014502075A1 (en) Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours